表纸
市场调查报告书

心脏生物标记的全球市场:成长率、趋势、预测

Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 567965
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
心脏生物标记的全球市场:成长率、趋势、预测 Cardiac Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

本报告提供全球心脏生物标记的市场相关分析,技术概要和市场基本结构,主要的推动及市场的阻碍要素,市场规模趋势预测 (今后6年份),各标记、各用途、各实施地点、各地区的详细趋势,市场竞争的动向,主要企业简介,今后的市场方向性等调查。

第1章 简介

第2章 摘要整理

第3章 主要影响要素

第4章 市场概要

  • 目前市场方案
  • 波特的五力分析

第5章 市场的推动因素与阻碍因素、机会、课题分析 (DROC分析)

  • 市场的推动要素
  • 市场的阻碍要素
  • 现在的市场机会
  • 主要课题

第6章 市场区隔

  • 标记的各类型
    • 肌酸激酶
    • 肌钙蛋白 (T,I)
    • 肌红蛋白
    • 钠利尿肽 (BNP,NT-proBNP)
    • 缺血修饰白蛋白
    • 其他
  • 各用途
    • 心肌梗塞
    • 鬱血性心衰竭
    • 急性冠状动脉症候群
    • 动脉粥状硬化
    • 其他
  • 实验的各实施地点
    • POC (Point of Care:临床现场) 检验
    • 实验室检验
  • 各地区
    • 北美 (美国,加拿大,墨西哥)
    • 欧洲 (英国,西班牙,义大利,法国,德国等)
    • 亚太地区 (日本,中国,印度,韩国,澳洲、纽西兰等)
    • 中东、非洲 (波灣合作理事会 (GCC) 各国,南非等)
    • 南美 (巴西,阿根廷等)

第7章 竞争环境

  • 企业合并、收购 (M&A)
  • 协定,产业合作、联盟
  • 新产品的销售

第8章 企业简介

  • Abbott laboratories
  • Alere Inc.
  • Siemens Healthcare
  • Roche Diagnostics Corporation
  • Beckman Coulter
  • Becton, Dickinson And Co.
  • Thermo Fisher Scientific
  • BioMerieux
  • Bio-Rad Laboratories
  • Randox laboratories

第9章 今后的市场方案

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 54449

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the cardiac biomarkers market are - Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cardiovascular Diseases
    • 4.2.2 Technological Advancements in the Cardiac Biomarkers
    • 4.2.3 Growing Funding From Public and Private Organizations for R&D
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Creatine Kinase
    • 5.1.2 Troponins
    • 5.1.3 Myoglobin
    • 5.1.4 Ischemia Modified Albumin
    • 5.1.5 Others
  • 5.2 By Application
    • 5.2.1 Congestive Heart Failure
    • 5.2.2 Acute Coronary Syndrome
    • 5.2.3 Myocardial Infarction
    • 5.2.4 Atherosclerosis
    • 5.2.5 Others
  • 5.3 By Location Of Testing
    • 5.3.1 Point of Care Testing
    • 5.3.2 Laboratory Testing
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 BioMerieux
    • 6.1.4 Bio-Rad Laboratories, Inc.
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Randox Laboratories
    • 6.1.8 Siemens Healthineers
    • 6.1.9 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top